Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The emergence of West Nile virus (WNV) in North America in 1999 as a cause of severe neurological disease in humans, horses and birds stimulated development of vaccines for human and veterinary use, as well as polyclonal/monoclonal antibodies and other immunomodulating compounds for use as therapeutics. Although disease incidence in North America has declined since the peak epidemics in 2002-2003, the virus has continued to be annually transmitted in the Americas and to cause periodic epidemics in Europe and the Middle East. Continued transmission of the virus with human and animal disease suggests that vaccines and therapeutics for the prevention and treatment of WNV disease could be of great benefit. This article focuses on progress in development and evaluation of vaccines and immunotherapeutics for the prevention and treatment of WNV disease in humans and animals.

Original languageEnglish (US)
Pages (from-to)269-285
Number of pages17
JournalImmunotherapy
Volume3
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

West Nile virus
Vaccines
Virus Diseases
North America
Infection
Viruses
Animal Diseases
Middle East
Human Development
Therapeutic Uses
Horses
Birds
Monoclonal Antibodies
Incidence
Therapeutics

Keywords

  • monoclonal antibodies
  • passive immunization
  • vaccine
  • West Nile virus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus. / Beasley, David.

In: Immunotherapy, Vol. 3, No. 2, 02.2011, p. 269-285.

Research output: Contribution to journalArticle

@article{3daf1d04b1834359aae6b5c8067c33c6,
title = "Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus",
abstract = "The emergence of West Nile virus (WNV) in North America in 1999 as a cause of severe neurological disease in humans, horses and birds stimulated development of vaccines for human and veterinary use, as well as polyclonal/monoclonal antibodies and other immunomodulating compounds for use as therapeutics. Although disease incidence in North America has declined since the peak epidemics in 2002-2003, the virus has continued to be annually transmitted in the Americas and to cause periodic epidemics in Europe and the Middle East. Continued transmission of the virus with human and animal disease suggests that vaccines and therapeutics for the prevention and treatment of WNV disease could be of great benefit. This article focuses on progress in development and evaluation of vaccines and immunotherapeutics for the prevention and treatment of WNV disease in humans and animals.",
keywords = "monoclonal antibodies, passive immunization, vaccine, West Nile virus",
author = "David Beasley",
year = "2011",
month = "2",
doi = "10.2217/imt.10.93",
language = "English (US)",
volume = "3",
pages = "269--285",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus

AU - Beasley, David

PY - 2011/2

Y1 - 2011/2

N2 - The emergence of West Nile virus (WNV) in North America in 1999 as a cause of severe neurological disease in humans, horses and birds stimulated development of vaccines for human and veterinary use, as well as polyclonal/monoclonal antibodies and other immunomodulating compounds for use as therapeutics. Although disease incidence in North America has declined since the peak epidemics in 2002-2003, the virus has continued to be annually transmitted in the Americas and to cause periodic epidemics in Europe and the Middle East. Continued transmission of the virus with human and animal disease suggests that vaccines and therapeutics for the prevention and treatment of WNV disease could be of great benefit. This article focuses on progress in development and evaluation of vaccines and immunotherapeutics for the prevention and treatment of WNV disease in humans and animals.

AB - The emergence of West Nile virus (WNV) in North America in 1999 as a cause of severe neurological disease in humans, horses and birds stimulated development of vaccines for human and veterinary use, as well as polyclonal/monoclonal antibodies and other immunomodulating compounds for use as therapeutics. Although disease incidence in North America has declined since the peak epidemics in 2002-2003, the virus has continued to be annually transmitted in the Americas and to cause periodic epidemics in Europe and the Middle East. Continued transmission of the virus with human and animal disease suggests that vaccines and therapeutics for the prevention and treatment of WNV disease could be of great benefit. This article focuses on progress in development and evaluation of vaccines and immunotherapeutics for the prevention and treatment of WNV disease in humans and animals.

KW - monoclonal antibodies

KW - passive immunization

KW - vaccine

KW - West Nile virus

UR - http://www.scopus.com/inward/record.url?scp=79951766069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951766069&partnerID=8YFLogxK

U2 - 10.2217/imt.10.93

DO - 10.2217/imt.10.93

M3 - Article

VL - 3

SP - 269

EP - 285

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 2

ER -